Margo Heath-Chiozzi - May 30, 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP OF REGULATORY AFFAIRS
Signature
/s/ Sam Martin, attorney-in-fact for Margo Heath-Chiozzi
Stock symbol
CLDX
Transactions as of
May 30, 2024
Transactions value $
-$1,192,856
Form type
4
Date filed
6/3/2024, 04:06 PM
Previous filing
Jun 20, 2023
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $80.8K +29.1K +240.35% $2.78* 41.2K May 30, 2024 Direct F1
transaction CLDX Common Stock Options Exercise $18.4K +2.04K +4.96% $9.02 43.2K May 30, 2024 Direct
transaction CLDX Common Stock Options Exercise $27.1K +2.61K +6.04% $10.38 45.8K May 30, 2024 Direct
transaction CLDX Common Stock Sale -$1.32M -38.7K -84.52% $34.07 7.09K May 30, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -29.1K -69.54% $0.00 12.7K May 30, 2024 Common Stock 29.1K $2.78 Direct F3
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -2.04K -24.52% $0.00 6.29K May 30, 2024 Common Stock 2.04K $9.02 Direct F4
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -2.61K -3.1% $0.00 81.4K May 30, 2024 Common Stock 2.61K $10.38 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 847 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 As of June 19, 2023, the option is fully vested.
F4 As of June 13, 2022, the option is fully vested.
F5 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.